Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 9

2.021 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 102 »» | Laatste | Omlaag ↓
  2. [verwijderd] 3 april 2007 15:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Gelukkig hebben Lawton en Finnegan beide senior positions gehad bij Genzyme.

    Genzyme heeft eerste marketing rechten Atryn US.
    Fijn bedrijf Genzyme.
    Vraag maar aan Pinto.
  5. [verwijderd] 3 april 2007 16:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

    Apr 3 2007, 4:00 AM EST
    PRNEWSWIRE
    www.genengnews.com/news/bnitem.aspx?n...

    ANNAPOLIS, Md., April 3 /PRNewswire/ -- PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that new data from its recombinant butyrylcholinesterase (rBChE) research program were recently presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases in Salzburg, Austria.

    New research conducted by Dr. Hermona Soreq and co-workers at the Alexander Silberman Life Sciences Institute at The Hebrew University of Jerusalem, in collaboration with PharmAthene, examined the role of recombinant butyrylcholinesterase (rBChE) in the formation of amyloid plaques, which are believed to play a crucial role in the development of Alzheimer's disease.

    The data presented by Drs. Soreq and Langermann, Vice President and Chief Scientific Officer for PharmAthene, show that rBChE can effectively block the formation of amyloid fibrils, precursors to plaque formation in the brain, potentially attenuating neurotoxicity. These data were substantiated by transmission electron microscopy studies, which showed that rBChE dramatically suppressed the formation of fibrils, resulting in thinner and less branched filaments than would normally occur in patients with Alzheimer's disease.

    Alzheimer's disease is a progressive neurodegenerative disease, which is estimated to affect more than 4.5 million Americans. One of the hallmarks of Alzheimer's disease is the accumulation of excessive amyloid plaques in areas of the brain that control memory and cognition. Amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between neurons. A growing body of scientific evidence suggests that the accumulation of amyloid plaques and neurofibrillary tangles in the brain may play an important role in the development and progression of Alzheimer's disease.

    "The role of amyloid plaques in the pathophysiology of Alzheimer's disease is well documented, and a number of approaches have been studied which attempt to block their formation by interfering at critical stages in this complex pathway," commented Hermona Soreq, Ph.D., Professor of Molecular Biology and Dean of Sciences at The Hebrew University. "Our preliminary results are especially intriguing as they suggest that rBChE is effective not only in inhibiting plaque formation, but also in potentially attenuating neurotoxicity. Examination of formed fibrils using a newly-developed, computer-aided and quantified electron microscopy method revealed that rBChE dramatically suppressed the formation of intermediary fibrils in the incubated mixtures which resulted in significantly fewer fibrils that were thinner and less branched than those formed without addition of rBChE. Fibril initiation is believed to be a precursor to amyloid plaque development. Together these results provide compelling evidence that rBChE serves as a natural protector against amyloid toxicity and support the development of rBChE as a therapeutic agent for patients with Alzheimer's disease."

    "Unlike human plasma-derived butyrylcholinesterase (HuBChE), which can only be produced in limited quantities, PharmAthene's rBChE is developed using a proprietary production system which enables large scale commercial production," commented Dr. Solomon Langermann, Vice President and Chief Scientific Officer for PharmAthene. "We are currently evaluating rBChE for the prevention and treatment of nerve agent toxicity and have obtained very promising results showing that rBChE provides enhanced survival without neurological impairment after exposure to nerve agents. To further this research, PharmAthene was recently awarded a contract from the Department of Defense for up to $213 million to support advanced development of rBChE."

    Dr. Langermann continued, "These recent data suggest a promising new potential therapeutic application for rBChE, which we intend to explore further. Our next steps, in collaboration with Dr. Soreq and her group, will include evaluating rBChE in animal models of Alzheimer's disease. If the results continue to be encouraging, then it would allow us to expand applications of rBChE therapy to areas other than nerve agent toxicity resulting in broader commercial applications with important benefits to society."

    The work conducted under the Alzheimer's research program is based on a patent owned by Yissum (the technology transfer company of The Hebrew University of Jerusalem), entitled "Human BChE Variants as Protectors from Amyloid Diseases," which has been licensed to PharmAthene.

    About Protexia(R): Recombinant Human Butyrylcholinesterase (rBChE)

    Protexia is a form of recombinant human butyrylcholinesterase (rBChE), a potent organophosphorus (OP) scavenger protein produced in the milk of transgenic goats, which is being developed for use as a prophylactic against acute organophosphorus (OP) nerve agent toxicity.

    Preclinical research conducted by PharmAthene's development partners, the US Army Medical Research Institute of Chemical Defense (USAMRICD) and DRDC Suffield, Defence Research and Development Canada, have demonstrated the capability of Protexia to protect laboratory animals from the toxic effects of chemical nerve agents.

    In these studies, pre-treatment with rBChE provided 100% survival against the nerve agents VX and soman. In post-exposure therapeutic studies, administration of rBChE following nerve agent exposure resulted in enhanced survival compared to control animals.

    While the utility of BChE to protect against nerve agent exposure is well documented, a major limitation in its development has been the inability to produce it in commercial volumes due to limited raw material availability, low levels of the enzyme in blood, and low production yields using traditional biotechnology methods. To overcome these limitations, PharmAthene has developed a recombinant form of human BChE, (rBChE), utilizing transgenic expression in goats which enables substantially higher production yields. PharmAthene believes that its transgenic technology will have the capacity to produce sufficient rBChE for both military and civilian defense.

  7. [verwijderd] 3 april 2007 17:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    psycho-pharma schreef:

    Dit soort nieuws moeten we vaker hebben!!!
    het verklaart de stijging van gisteren.

    P.
    jammer dat het niet doorzet, dan hadden we er meer aan , maar ja geduld he......
  9. [verwijderd] 3 april 2007 18:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ohmygod schreef:

    Ze zijn een erg goede basis aan het leggen....
    Hopelijk gaan we daar op korte termijn (resterend 2007) koerstechnisch ook iets van vernemen.

    $0.95/1.10 is voor bedrijven zoals Insmed,bedrijven die diep in de shit zitten.
    De hedendaagse koers is GTCB onwaardig,en geeft totaal niet weer dat men goed bezig is.
  10. [verwijderd] 3 april 2007 18:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    "The approval in Europe validates our production technology for ATryn® and our portfolio of programs, enabling us to pursue our strategy for partnering and commercializing our products," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "I am pleased that executives of the caliber of Ashley Lawton and Rick Finnegan have joined us as we pursue our partnering and commercialization goals."

    Mooi nieuws,ben benieuwd wat het gaat kosten.

    Groet.

  12. [verwijderd] 3 april 2007 18:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    wishdom schreef:

    "The approval in Europe validates our production technology for ATryn® and our portfolio of programs, enabling us to pursue our strategy for partnering and commercializing our products," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "I am pleased that executives of the caliber of Ashley Lawton and Rick Finnegan have joined us as we pursue our partnering and commercialization goals."

    Mooi nieuws,ben benieuwd wat het gaat kosten.

    Groet.

    Zijn dit niet de regels van de economie ?!
    Eerst investeren om daarna te renderen !!

    Niks, voor niks wish.
  13. [verwijderd] 3 april 2007 19:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Natuurlijk met je eens,maar je moet wel uitkijken dat je geen productie bedrijf wordt,maar ook de commercie in de gaten houden.

    En de aandeelhouders willen uiteindelijk ook renderen.

    Groet.
  16. [verwijderd] 3 april 2007 20:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    quote:

    psycho-pharma schreef:

    + 3 cents

    Het loopt dus door omhoog.

    Wellicht een geleidelijke opmaat voor een overname dit jaar.

    ??

    Psycho
    [/quote]

    [quote=orchid]
    $1,13.......

    we gaan dus door omhoog,

    overname , kans erg groot
    De neuzen wijzen blijkbaar meer en meer in dezelfde richting, alhoewel ik me de vraag stel welke hiervan/hiervoor de indicatoren mogen zijn ?!
    Twee dagen stijging onder vrij zwak volume, laat ze maar rustig onder de leuze, traag maar gestaag !!
    En hopelijk geen overname, want dan proberen ze ons misschien wel tevreden te stellen met een dode mus.

    1.13
2.021 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 102 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.196
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.517
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.651
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.995
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.322
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.717
AMG 971 133.054
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 483
Antonov 22.632 153.605
Aperam 92 14.918
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.571
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.993
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390